Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28840671 | 0.81 | HTR2C (0.48) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL29925168 | 0.81 | HTR2C (0.48) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL29924782 | 0.80 | HTR2C (0.49) | NPC1DGAT1 | |
| SCHEMBL28841058 | 0.80 | HTR2C (0.51) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL29924561 | 0.80 | HTR2C (0.51) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL28840665 | 0.80 | HTR2C (0.49) | NPC1DGAT1 | |
| SCHEMBL4493915 | 0.80 | HTR2C (0.49) | NPC1DGAT1 | |
| SCHEMBL1467091 | 0.80 | HTR2A (0.49) | NPC1DGAT1 | |
| SCHEMBL28840999 | 0.80 | DGAT1 (0.36) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL29924680 | 0.80 | DGAT1 (0.36) | NPC1DGAT1EGFRIGF1RSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100577660-C | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists used for the treatment of diabetes | HOFFMANN LA ROCHE | 2010-01-06 | — | — | CN | disclosed |
| EP-1539746-B1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | EP | disclosed |
| EP-1622895-A2 | 1-ARYL-3-(INDOL-5-YL)-PROP-2-EN-1-ONES, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-02-08 | — | — | EP | disclosed |
| CN-1681808-A | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2005-09-15 | — | — | US | disclosed |
| EP-1539746-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6890947-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-10 | — | — | US | disclosed |
| CN-1612856-A | 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof | AVENTIS PHARMA SA (FR) | 2005-05-04 | — | — | CN | disclosed |
| WO-2004099193-A2 | 1-ARYL-3-(INDOL-5-YL)-PROP-2-EN-1-ONES, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229931-A1 | 1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use | AVENTIS PHARMA S. A. (FR) | 2004-11-18 | — | — | US | disclosed |
| EP-1453790-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | disclosed |
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| WO-2004024726-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053979-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-18 | — | — | US | disclosed |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | AVENTIS PHARMA S.A. | 2003-08-14 | — | — | US | disclosed |
| WO-2003048106-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147584-A2 | 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | MCL1, ENPP1, MYC | CYP2A6 1109/4885PLA2G4A 406/4885PTGER4 661/4885 |
| US-20040229931-A1 | 1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use | IDO1, AHR, MCL1 | CYP2A6 1354/4885PLA2G4A 484/4885PTGER4 1444/4885 |
| US-20040053979-A1 | Indolyl derivatives | UGT1A8, CYP2C8, UGT1A1 | CYP2A6 49/4885PLA2G4A 2486/4885PTGER4 1318/4885 |
| US-20050203170-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | CYP2A6 1109/4885PLA2G4A 406/4885PTGER4 661/4885 |
| US-20030153611-A1 | 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof | MCL1, ENPP1, MYC | CYP2A6 1109/4885PLA2G4A 406/4885PTGER4 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.